JP2021513865A5 - - Google Patents

Info

Publication number
JP2021513865A5
JP2021513865A5 JP2020544642A JP2020544642A JP2021513865A5 JP 2021513865 A5 JP2021513865 A5 JP 2021513865A5 JP 2020544642 A JP2020544642 A JP 2020544642A JP 2020544642 A JP2020544642 A JP 2020544642A JP 2021513865 A5 JP2021513865 A5 JP 2021513865A5
Authority
JP
Japan
Prior art keywords
streptococcus
group
amino acid
modified lysin
lysin polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513865A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/019638 external-priority patent/WO2019165454A1/en
Publication of JP2021513865A publication Critical patent/JP2021513865A/ja
Publication of JP2021513865A5 publication Critical patent/JP2021513865A5/ja
Pending legal-status Critical Current

Links

JP2020544642A 2018-02-26 2019-02-26 修飾PlySs2溶解素及びその使用 Pending JP2021513865A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862635515P 2018-02-26 2018-02-26
US62/635,515 2018-02-26
PCT/US2019/019638 WO2019165454A1 (en) 2018-02-26 2019-02-26 Modified plyss2 lysins and uses thereof

Publications (2)

Publication Number Publication Date
JP2021513865A JP2021513865A (ja) 2021-06-03
JP2021513865A5 true JP2021513865A5 (cg-RX-API-DMAC7.html) 2022-02-09

Family

ID=67687985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544642A Pending JP2021513865A (ja) 2018-02-26 2019-02-26 修飾PlySs2溶解素及びその使用

Country Status (12)

Country Link
US (1) US20210032294A1 (cg-RX-API-DMAC7.html)
EP (1) EP3758738A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021513865A (cg-RX-API-DMAC7.html)
KR (1) KR20200124724A (cg-RX-API-DMAC7.html)
CN (1) CN112118861A (cg-RX-API-DMAC7.html)
AU (1) AU2019224160A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017219A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092109A1 (cg-RX-API-DMAC7.html)
IL (1) IL276807A (cg-RX-API-DMAC7.html)
MX (1) MX2020008860A (cg-RX-API-DMAC7.html)
RU (1) RU2020128276A (cg-RX-API-DMAC7.html)
WO (1) WO2019165454A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020271116A1 (en) * 2019-04-11 2021-11-11 Contrafect Corporation Method of treating and preventing bone and joint infections
US20230277632A1 (en) * 2020-05-19 2023-09-07 Contrafect Corporation MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA
WO2023049747A1 (en) * 2021-09-22 2023-03-30 Elanco Us Inc. Streptococcus suis lytic enzyme compositions and methods of use thereof
WO2023081691A1 (en) * 2021-11-04 2023-05-11 Contrafect Corporation Method of treating and preventing bone and joint infections
CN115851689A (zh) * 2022-08-09 2023-03-28 中南民族大学 一种嵌合裂解酶PlySs2E-V12C及其应用、重组质粒和重组菌株

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383544B (es) * 2011-04-21 2025-03-14 Univ Rockefeller Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas
DK3085777T3 (da) * 2011-05-04 2020-02-03 Micreos Human Health Bv Polypeptid
AU2013259512B2 (en) * 2012-05-09 2018-01-25 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
RU2646102C2 (ru) * 2012-05-09 2018-03-01 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага
CN104073478A (zh) * 2014-06-13 2014-10-01 上海交通大学 杀灭革兰氏阳性菌的酶抗生素及其制备、用途
CN104211781A (zh) * 2014-09-04 2014-12-17 北京纳百景弈生物科技有限公司 金黄色葡萄球菌裂解蛋白的制备方法及其应用
CN109152822B (zh) * 2016-05-12 2023-12-05 抗非特公司 用于评估和确定抗菌多肽的最小抑制浓度的肉汤微量稀释法

Similar Documents

Publication Publication Date Title
Al Atya et al. Anti-MRSA activities of enterocins DD28 and DD93 and evidences on their role in the inhibition of biofilm formation
Mathur et al. Fighting biofilms with lantibiotics and other groups of bacteriocins
JP2022058682A5 (cg-RX-API-DMAC7.html)
RU2020128276A (ru) МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
Gibbons et al. The effect of reserpine, a modulator of multidrug efflux pumps, on the in vitro activity of tetracycline against clinical isolates of methicillin resistant Staphylococcus aureus (MRSA) possessing the tet (K) determinant
Tagg Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius
RU2014149351A (ru) Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
RU2018102796A (ru) Предотвращение, разрушение и обработка биопленки лизином бактериофага
JP2021519083A5 (cg-RX-API-DMAC7.html)
Fan et al. Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria
Basi-Chipalu et al. A review on characterization, applications and structure-activity relationships of Bacillus species-produced bacteriocins
Du et al. Transcriptomic and proteomic profiling response of methicillin-resistant Staphylococcus aureus (MRSA) to a novel bacteriocin, plantaricin GZ1-27 and its inhibition of biofilm formation
Hwang et al. Engineering microbes for targeted strikes against human pathogens
JP2017533177A5 (cg-RX-API-DMAC7.html)
HRP20200195T1 (hr) Antibiotske terapije na bazi peptida porijeklom od vodenog bivola
Chen et al. Engineered endolysin of Klebsiella pneumoniae phage is a potent and broad-spectrum bactericidal agent against “ESKAPEE” pathogens
Rahimzadeh et al. Endolysins of bacteriophages as an anti-methicillin resistant staphylococcus aureus infection in children: a narrative review
WO2010041970A3 (en) Antibacterial phage peptides and methods of use thereof
JP2021519311A5 (cg-RX-API-DMAC7.html)
JP2020527164A (ja) グラム陰性病原体に対する抗微生物活性を示す抗微生物ペプチド及びその混合物
JP2012504958A5 (cg-RX-API-DMAC7.html)
US12342819B2 (en) Elasnin, a bacteriostatic agent that has potent antibiofilm activities against both mono- and multi-species biofilm
Alba et al. Peptides DLL37-1 and LL37-1, an alternative to inhibit biofilm formation in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis
Ohdan et al. Staphylococcus capitis strain producing dual bacteriocins, capidermicin and micrococcin P1, shows broad-spectrum antimicrobial activity
Ulm et al. Targeting bactoprenol-coupled cell envelope precursors